Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 1994, for Schering-Plough Corporation. The company operates primarily in pharmaceutical and health care products. The filing notes that the company is subject to competitive pricing pressures in the U.S. due to managed care and potential government health care reform, as well as cost-containment programs in international markets.
Key Financial Metrics
| Metric | Q1 1994 | Q1 1993 |
|---|---|---|
| Sales | $1,161.6 million | $1,089.6 million |
| Net Income | $253.2 million | $129.3 million |
| EPS (Diluted) | $1.31 | $0.65 |
| Operating Cash Flow | $142.2 million | $99.2 million |
| Cash & Equivalents | $110.6 million | $160.6 million |
| Total Debt (Short + Long Term) | $1,093.3 million | Filing text does not provide a clear Q1 1993 total debt figure |
| Net Debt Position | $862.6 million | $824.3 million (Year-end 1993) |
Margins: Income before taxes represented 28.7% of sales in Q1 1994, up from 26.8% in Q1 1993. Cost of sales declined to 21.3% of sales from 21.5%.
Material Changes vs. Prior Period
- Revenue Growth: Consolidated sales increased 7% ($72.0 million) year-over-year. Excluding foreign currency effects, sales advanced 8%.
- Profitability: Net income more than doubled to $253.2 million. This increase is partially attributable to a one-time cumulative effect of an accounting change in Q1 1993 (SFAS No. 106) which reduced 1993 net income by $94.2 million. Excluding this, earnings per share before the accounting change rose 16% to $1.31.
- Product Performance:
- Domestic: Prescription pharmaceutical sales rose 15%, driven by a 30% increase in respiratory products (CLARITIN, PROVENTIL). Vision care sales rose 39%.
- International: Pharmaceutical sales grew 7% excluding currency impacts. Sales in Japan declined due to lower sales of INTRON A and government-mandated price reductions.
- Balance Sheet: Cash and cash equivalents decreased by $111.6 million. Total debt decreased by $165.0 million during the quarter, but the net debt position increased slightly due to the larger decline in cash and investments.
Guidance, Outlook, and Risks
- Outlook: Management expects total 1994 sales of INTRON A in Japan to decline further. Total R&D expenses are anticipated to approximate $630 million for 1994.
- Tax Impact: The Omnibus Budget Reconciliation Act of 1993 is expected to unfavorably impact the effective tax rate by an additional 1.5 to 2.0 percentage points by 1996.
- Regulatory Risks: The Clinton health care reform proposal could impact operations through requirements for prescription drug coverage and Medicare rebates. Generic competition for PROVENTIL is expected to negatively affect sales and profitability starting late 1994 or early 1995.
- Legal Proceedings: The company is a defendant in over 60 antitrust lawsuits alleging price-fixing and price discrimination. Management believes these actions will not have a material adverse effect on financial position.
- Share Repurchases: The company is approximately 84% complete with a $500 million share repurchase program authorized in February 1993.
Investor Verification Checklist
- Verify the impact of the SFAS No. 106 accounting change on the year-over-year comparison of net income and EPS.
- Monitor the timeline for generic entry into the PROVENTIL market and its potential impact on respiratory product margins.
- Assess the progress and potential outcome of the 60+ antitrust lawsuits filed against the company.
- Track the implementation of U.S. health care reform proposals and their effect on pricing and Medicare rebates.
- Review the completion status of the $500 million share repurchase program and future capital allocation plans.